期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 139, 期 3, 页码 434-438出版社
BLACKWELL PUBLISHING
DOI: 10.1111/j.1365-2141.2007.06829.x
关键词
bortezomib; osteoblast; myeloma; Dkk1; bone
类别
资金
- NCI NIH HHS [K01 CA104180, P01 CA040035] Funding Source: Medline
Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mouse calvarial cultures; this effect was blocked by dickkopf 1(Dkk1), an antagonist of Wnt signalling implicated in myeloma bone disease. Bortezomib inhibited Dkk1 expression in calvariae and bone marrow-derived stromal cells, suggesting a novel mechanism by which bortezomib exerts its effects in bone. Clinical trials in patients with myeloma bone disease are needed to validate these results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据